Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
International Journal of Clinical Oncology|September 1, 2025
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in JapanDaisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, et al.
BMC Cancer|April 22, 2020
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinomaHideaki Bando, Daisuke Kotani, Takahiro Tsushima, et al.
Clinical Colorectal Cancer|March 29, 2024
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramDaisuke Kotani, Atsuo Takashima, Takeshi Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal CancerSatoshi Fujii, Daisuke Kotani, Masahiro Hattori, et al.
Cancer Science|February 8, 2022
Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiationJunyan Du, Shun-Ichiro Kageyama, Riu Yamashita, et al.
Communications Biology|August 5, 2023
Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathwaysJunyan Du, Shun-Ichiro Kageyama, Riu Yamashita, et al.
Med (New York, N.Y.)|June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRCHideaki Bando, Daisuke Kotani, Hironaga Satake, et al.
ESMO Open|December 5, 2019
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, et al.
ESMO Open|February 8, 2021
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancerDaisuke Kotani, Hideaki Bando, Hiroya Taniguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 TherapyKeigo Chida, Akihito Kawazoe, Toshihiro Suzuki, et al.
Pageof 9